Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | V600_K601delinsE |
Impact List | indel |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF V600_K601delinsE results in the deletion of two amino acids formation of a new glutamic acid (E) residue in the protein kinase domain of the Braf protein between amino acids 600 and 601 (UniProt.org, PMID: 22563563). V600_K601delinsE leads to activation of downstream Mek and Erk signaling, increased colony formation (PMID: 17297294), and induces cell proliferation and cell viability in cell culture (PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF V600_K601delinsE |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753334_140753336delTCA |
cDNA | c.1799_1801delTGA |
Protein | p.V600_K601delinsE |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354609.2 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753334_140753336delTCA | c.1799_1801delTGA | p.V600_K601delinsE | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Active, not recruiting | CAN | 0 |
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |